- Home
- ACIC vs RAPT Comparison
ACIC vs RAPT Comparison
Compare ACIC & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- RAPT
- Stock Information
- Founded
- ACIC 1999
- RAPT 2015
- Country
- ACIC United States
- RAPT United States
- Employees
- ACIC N/A
- RAPT N/A
- Industry
- ACIC Property-Casualty Insurers
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- RAPT Health Care
- Exchange
- ACIC Nasdaq
- RAPT Nasdaq
- Market Cap
- ACIC 546.2M
- RAPT 498.4M
- IPO Year
- ACIC N/A
- RAPT 2019
- Fundamental
- Price
- ACIC $12.11
- RAPT $28.69
- Analyst Decision
- ACIC Buy
- RAPT Buy
- Analyst Count
- ACIC 1
- RAPT 7
- Target Price
- ACIC $16.00
- RAPT $35.14
- AVG Volume (30 Days)
- ACIC 156.9K
- RAPT 321.0K
- Earning Date
- ACIC 11-05-2025
- RAPT 11-11-2025
- Dividend Yield
- ACIC 4.13%
- RAPT N/A
- EPS Growth
- ACIC 14.01
- RAPT N/A
- EPS
- ACIC 1.63
- RAPT N/A
- Revenue
- ACIC $320,072,000.00
- RAPT N/A
- Revenue This Year
- ACIC $4.91
- RAPT N/A
- Revenue Next Year
- ACIC $4.16
- RAPT N/A
- P/E Ratio
- ACIC $7.42
- RAPT N/A
- Revenue Growth
- ACIC 33.90
- RAPT N/A
- 52 Week Low
- ACIC $8.82
- RAPT $5.67
- 52 Week High
- ACIC $15.08
- RAPT $32.35
- Technical
- Relative Strength Index (RSI)
- ACIC 65.32
- RAPT 77.62
- Support Level
- ACIC $11.04
- RAPT $24.34
- Resistance Level
- ACIC $11.45
- RAPT $32.35
- Average True Range (ATR)
- ACIC 0.29
- RAPT 2.74
- MACD
- ACIC 0.06
- RAPT 0.48
- Stochastic Oscillator
- ACIC 96.46
- RAPT 72.42
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.